Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (NorTick_EM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01368341|
Recruitment Status : Completed
First Posted : June 7, 2011
Last Update Posted : December 12, 2014
|Condition or disease||Intervention/treatment||Phase|
|Erythema Migrans Erythema Chronicum Migrans Borreliosis Lyme Disease Early Lyme Disease||Drug: Doxycycline Drug: Phenoxymethylpenicillin Drug: Amoxicillin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||225 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline.|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2014|
Active Comparator: Doxycycline
Doxycycline, 100 mg, tablets, b.i.d., 14 days
1 tablet, 100 mg, b.i.d. 14 days
Other Name: Doksycycline 100 mg HEXAL, no. 30
Active Comparator: Penicillin
Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
Tablet 650 mg, 2 tablets, t.i.d., 14 days
Other Name: Weifapenin 650 mg, WEIFA, no. 100
Active Comparator: Amoxicillin
Amoxicillin 500 mg capsula, t.i.d., 14 days
Capsula, 500 mg, t.i.d., 14 days
Other Name: Amoxicillin 500 mg MYLAN, no. 30 + 20.
- Duration of Erythema migrans (EM) [ Time Frame: 1-90 days ]On day 1 duration until first the consulation is registered. Day 1-14 the EM is registered in a patient diary. On day 14 the doctor is asked whether the EM has disseapeared. If not the patient is followed by phone from the researchers. On day 90 they are additionally asked for how long it lasted.
- Subjective Health Complaints (SHC) [ Time Frame: 1 year ]By questionnaire on day 1, day 90 and day 360 the patients are asked about their SHC which is a standardized set of parametres. The 3 treatment groups are compaired to each other and to 1200 healthy blood donors receiving the same questionnaire. There are 29 standardized and 3 Lyme disease related subjects to be measured.
- Borrelia antibodies [ Time Frame: 1-90 days ]Normally antibody production is not measured for EM as it is a clinical diagnosis, and less than 50 percent of EM-patients are expected to develop antibodies in the first period. However antibodies are here measured on day 1, day 14 and day 90 to see whether there are differences between the groups. Also the results will be compared to the blood donors.
- Side symptoms [ Time Frame: 1-14 days ]
The EM in it self is often asymptomatic, and fever, headache and nerval palsy can be a sign of disseminated disease or co-infection. On the quiestionnaire to the pasient and doctor on day 1, in the patient diary day 1-14 and on the questionnaire to the doctor on day 14 these side symptoms are registered.
In a potential case, where it turns out that the patient suffers from disseminated disease this will be regostered as treatment failure in the study and the patient treated and/or referred as normal.
- Side effects [ Time Frame: 1-14 days ]The antibiotic tretments are expected to be non-inferior to each other. Potensial side effects as nausea, diarrhea etc. are registered in the patients diary day 1-14 and in the doctors quiestionnaire on day 14.
- Subgrouping and TBE [ Time Frame: 1-14 days ]For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgroupring of the Borrelia bacteria. TBE-antibodies are measured on day 14.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01368341
|Antibiotic Centre for Primary Care, University of Oslo|
|Oslo, Norway, 0318|
|Principal Investigator:||Morten Lindbak, Professor||University of Oslo|